Fort Point Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Fort Point Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$265K	Buy	593 +27	+5%	+$12.6K	0.03%	193
2025 Q4	$248K	Sell	566 -21	-4%	-$9.05K	0.03%	212
2025 Q3	$230K	Sell	587 -121	-17%	-$50.6K	0.03%	201
2025 Q2	$315K	Buy	708 +34	+5%	+$15.7K	0.02%	275
2025 Q1	$327K	Sell	674 -146	-18%	-$68K	0.04%	260
2024 Q4	$330K	Buy	820 +132	+19%	+$61.2K	0.04%	252
2024 Q3	$320K	Buy	688 +158	+30%	+$75.9K	0.04%	234
2024 Q2	$248K	Sell	530 -15	-3%	-$6.51K	0.03%	276
2024 Q1	$228K	Hold	545	–	–	0.03%	295
2023 Q4	$222K	Buy	+545	New	+$201K	0.03%	270

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fort Point Capital Partners's VRTX Position: Q1 2026 in Review

Fort Point Capital Partners increased its Vertex Pharmaceuticals (VRTX) stake by 4.8% in Q1 2026, buying an estimated $12.6K and bringing the position to 593 shares worth $265K. The position accounts for 0.03% of the portfolio, ranked #193.

Fort Point Capital Partners first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $330K in Q4 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Fort Point Capital Partners held 593 shares of Vertex Pharmaceuticals worth $265K as of Q1 2026.
Fort Point Capital Partners bought 27 Vertex Pharmaceuticals shares in Q1 2026, an estimated $12.6K.
Vertex Pharmaceuticals made up 0.03% of Fort Point Capital Partners's portfolio in Q1 2026, its #193 holding.
Fort Point Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Fort Point Capital Partners's Vertex Pharmaceuticals position peaked at $330K in Q4 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fort Point Capital Partners's 13F filing for Q1 2026, filed 14 May 2026.